2Teachey DT, Seif AE, Grupp SA. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS) [J]. BrJ Haematol, 2010, 148(2): 205-216.
3Bleesing J J, Brown MR, Straus SE, et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome[ J ]. Blood, 2001, 98(8): 2466-2473.
4Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations mad defective lymphocyte apoptosis [J]. Blood, 2001, 98( 1 ) : 194-200.
5Oliveira JB, Bleesing J J, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphopwliferative syndrome(ALPS) : report from the 2009 NIH International Workshop [J]. Blood, 2010, 116 (14) : 35-40.
6Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome[J]. Cell, 1995, 81(6) : 935-946.
7Seif AE, Manno CS, Sheen C, et al. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study [J]. Blood, 2010, 115 (11 ) : 2142-2145.
